Hope for tots with rare immune disease in new drug trial
NCT ID NCT05693129
Summary
This study is testing a drug called leniolisib in very young children (ages 1 to 6) who have a rare genetic immune disorder called APDS. The goal is to see if the drug is safe and effective at controlling the disease by reducing swollen lymph nodes and infections. The children will take the drug orally for a year to see how well it works over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Great Ormond Street Hospital
London, WC1N3JH, United Kingdom
-
Hospital Pediátrico de Coimbra da ULS Coimbra UNIDADE LOCAL DE SAÚDE DE COIMBRA
Coimbra, 3000-075, Portugal
-
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
-
Institute of Science Tokyo Hospital
Tokyo, 113-8519, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
National Institutes of Health
Bethesda, Maryland, 20814, United States
-
Rainbow Childrens Hospital
Shaker Heights, Ohio, 44122, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.